Evidence map›Paper›PMID 42791913›Full record

ArticleBioengineering (Basel, Switzerland)2026

Multimodal Retinal Imaging for the Detection of Early Alzheimer's Disease: Combining Biochemical, Structural, and Vascular Biomarkers.

Michiel Ghesquiere, Eirini Christinaki, Sophie Lemmens, Jan Van Eijgen, Lennert Beeckmans, Achilleas Ghinis, Thomas Jacobs, Karel Van Keer, Zahi Wehbi, Lies De Groef and 11 more

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Michiel GhesquiereResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0009-0006-1476-2761
Eirini ChristinakiResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-5785-1509
Sophie LemmensResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0002-6842-1747
Jan Van EijgenResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-7243-9280
Lennert BeeckmansResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.
Achilleas GhinisResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0002-7111-8853
Thomas JacobsResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0009-0001-0424-389X
Karel Van KeerResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.
Zahi WehbiResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0009-0007-0405-7011
Lies De GroefDepartment of Biology, Animal Physiology and Neurobiology, KU Leuven, Naamsestraat 59, 3000 Leuven, Belgium.ORCID 0000-0002-3329-3474
Yasmin Dahdouh-GuebasDepartment of Biology, Animal Physiology and Neurobiology, KU Leuven, Naamsestraat 59, 3000 Leuven, Belgium.
Wouter CharleImec, Kapeldreef 75, 3001 Leuven, Belgium.
Thomas Vande CasteeleDepartment of Neurosciences-Neuropsychiatry, Leuven Brain Institute, KU Leuven, UZ Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0002-1559-4038
Mathieu VandenbulckeDepartment of Neurosciences-Neuropsychiatry, Leuven Brain Institute, KU Leuven, UZ Herestraat 49, 3000 Leuven, Belgium.
Greet VanderlindenNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, UZ Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0002-5673-4121
Koen Van LaereNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospitals Leuven, UZ Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-5200-7245
Jolien SchaeverbekeLaboratory of Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-2257-0568
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven, 3000 Leuven, Belgium.
Jenny CeccariniDepartment of Neurosciences, Leuven Brain Institute, KU Leuven, Biomedical Sciences Group, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0003-2774-9516
Maarten De VosDynamical Systems, Signal Processing and Data Analytics (STADIUS), Department of Electrical Engineering (ESAT), KU Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium.
Ingeborg StalmansResearch Group Ophthalmology, Department of Neurosciences, KU Leuven, ON5 Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-7507-4512

Funding

Internationale Stichting Alzheimer Onderzoek 2020/0032, 2021/0036KU Leuven C24-17-063KU Leuven C24/18/095KU Leuven Sequoia Fund for Research on Ageing and Mental HealthResearch Foundation - Flanders 1292326NResearch Foundation - Flanders 12Y1623NResearch Foundation - Flanders 12ZZM23NResearch Foundation - Flanders 1SHC824NResearch Foundation - Flanders FWO-ERANET S007721NResearch Foundation - Flanders G093218NResearch Foundation - Flanders G0C0319N
6 · The paper itself

Abstract

Alzheimer's disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging-hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)-can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ- cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell-inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for an exploratory cross-sectional comparison across disease-stage groups. HSI showed nominally lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (AUC = 0.72). GC-IPL thickness showed a similar inferior-predominant regional pattern. Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), although this improvement over the unimodal models did not reach statistical significance, whereas vascular biomarkers contributed minimally. In an exploratory cross-sectional comparison across AD stage groups drawn from two cohorts, HSI features showed a non-monotonic pattern, decreasing in early Aβ+ stages and rising again in dementia. These findings provide preliminary evidence of complementary information between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.

Indexed as

Alzheimer’s diseasehyperspectral imagingmachine learningoptical coherence tomographyretinal imagingvascular biomarkers

Identifiers

PMID42791913
PMCPMC13603378

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.